Monday, 20 May 2019

You are here

Febuxostat (IR or XR) Effective in Gout with Renal Impairment

Saag and colleagues report the results of a 3 month phase III trial demonstrating equal efficacy between febuxostat extended release (XR) and immediate release (IR) formulations in patients with gout.  and normal or impaired renal function.

This multicenter, placebo-controlled, double-blind study enrolled 1790 gout patients with normal or impaired (mild to severe) renal function and randomized them to receive placebo, febuxostat IR 40 or 80 mg, or febuxostat XR 40 or 80 mg once daily (1:1:1:1:1 ratio).

Febuxostat in either formulation was significantly better at achieving sUA <5.0 mg/dL or sUA <6.0 mg/dL at Month 3 (P<0.001 versus placebo).

While both febuxostat XR and IR had similar effects on sUA endpoints, significantly more patients achieved sUA <5.0 mg/dL with XR 40 mg versus IR 40 mg.

Flare rates were similar across all treatment groups and no new or extraordinary safety concerns were raised by these studies. Adverse events were low in frequency and lead by  diarrhea, nasopharyngitis, and hypertension.

Both febuxostat formulations were well tolerated and equally effective (sUA) in patients with normal and impaired renal function. These data do add to the growing body of evidence supporting the use of febuxostat in the management of hyperuricemia in patients with renal impairment.  

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Coexistent Gout Increases Risk in Rheumatoid Arthritis

It his often said that gout and rheumatoid arthritis (RA) cannot coexist and where confusion exists, a good history and testing for serum urate (SUA) and rheumatoid factor (RF) can usually clarify the dominant disorders. A recent study shows that hyperuricemia and gout are uncommon in RA, but when present shows an increased risk of comorbidities and cardiovascular (CV) mortality.

Less Structural Damage with T2T in Gout

A two‐year randomized clinical trial has demonstrated that allopurinol dose escalation to a target serum urate (SU) results in less bone erosion, structural damage and urate crystal deposition in patients with gout.

Ideal Outcomes are Seldom Achieved in Gout

Studies from a cohort of gout patients in Mexico shows that long-term goals of a target serum urate (sUA) < 6 mg/dL and remission are rare, especially for those with severe gout.

Omega-3 Rich Fish Lowers Gout Flares

Boston researchers have shown that consumption of fish rich in omega‐3 polyunsaturated fatty acids (n‐3 PUFA) leads to a lower risk of recurrent gout flares.

Chronic Kidney Disease Augments Gout Risks

A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.

A retrospective population-based cohort study of incident gout between 2006-2009 identified those with CKD; defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date.